The APP ordered a bilateral diagnostic mammogram and left breast ultrasound that revealed extremely dense breast tissue, a ...

This episode’s guest, Melinda Mayorga, RN, MSN, CNS, AGCNS-BC, OCN, a clinical nurse specialist at Norris Comprehensive ...

The FDA has approved the use of subcutaneous amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) for use in all approved ...

CAR T-cell therapy has revolutionized the treatment of certain hematologic malignancies, providing durable remissions for ...

Young, Empowered, and Strong (YES), a mobile health intervention, was linked to improved general and cancer-specific ...

Hormone replacement therapy (HRT) does not have an adverse effect on breast cancer risk, according to findings from an ...

The FDA has granted standard approval to rucaparib (Rubraca) for the treatment of patients with metastatic ...

Oncology nurses and APPs are key players in patient education on precision medicine.

The FDA has granted accelerated approval to subcutaneous treatment with mosunetuzumab (Lunsumio VELO™), a CD20xCD3 bispecific antibody, for adult patients with relapsed or refractory follicular ...

Deborah (Debi) A. Boyle MSN, RN, AOCNS, FAAN, is editor in chief of Oncology Nursing News®. She is a long tenured oncology clinical nurse specialist who has practiced in both Comprehensive Cancer ...

A nurse-driven palliative care referral intervention demonstrated preliminary success in increasing the number of patients who received this form of supportive care. To combat this discrepancy, a ...

For most JAK inhibitors dosing starts at the maximum safe dose, while ruxolitinib often requires lower initial doses and dose reductions over the first 12 weeks when cytopenias typically worsen before ...